283 related articles for article (PubMed ID: 36646046)
21. Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer.
McElree IM; Steinberg RL; Martin AC; Richards J; Mott SL; Gellhaus PT; Nepple KG; O'Donnell MA; Packiam VT
J Urol; 2022 Sep; 208(3):589-599. PubMed ID: 35892270
[TBL] [Abstract][Full Text] [Related]
22. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
[TBL] [Abstract][Full Text] [Related]
23. Impact of maintenance therapy using a half dose of the bacillus Calmette-Guérin Tokyo strain on recurrence of intermediate and high-risk nonmuscle invasive bladder cancer: a retrospective single-center study.
Koguchi D; Matsumoto K; Hirayama T; Moroo S; Kobayashi M; Katsumata H; Ikeda M; Iwamura M
BMC Urol; 2020 Dec; 20(1):194. PubMed ID: 33298034
[TBL] [Abstract][Full Text] [Related]
24. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
[TBL] [Abstract][Full Text] [Related]
25. C-reactive protein as a prognostic predictor for non-muscle invasive bladder cancer after intravesical bacillus Calmette-Guérin therapy: A Japan Urological Oncology Group study analysis.
Nishikawa R; Miyake M; Morizane S; Shimizu R; Teraoka S; Honda M; Iida K; Nishimura N; Sazuka T; Kimura T; Ito A; Shiga K; Taoka R; Kojima T; Kobayashi T; Nishiyama N; Kitamura H; Nishiyama H; Fujimoto K; Takenaka A
Int J Urol; 2023 Mar; 30(3):299-307. PubMed ID: 36448522
[TBL] [Abstract][Full Text] [Related]
26. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF
J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006
[TBL] [Abstract][Full Text] [Related]
27. CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer.
Steinberg GD; Shore ND; Redorta JP; Galsky MD; Bedke J; Ku JH; Kretkowski M; Hu H; Penkov K; Vermette JJ; Tarazi JC; Randall AE; Pierce KJ; Saltzstein D; Powles TB
Future Oncol; 2024 May; 20(14):891-901. PubMed ID: 38189180
[TBL] [Abstract][Full Text] [Related]
28. Non-maintenance intravesical Bacillus Calmette-Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study.
Miyake M; Iida K; Nishimura N; Miyamoto T; Fujimoto K; Tomida R; Matsumoto K; Numakura K; Inokuchi J; Morizane S; Yoneyama T; Matsumura Y; Abe T; Inoue M; Yamada T; Terada N; Hirao S; Uemura M; Matsushita Y; Taoka R; Kobayashi T; Kojima T; Matsui Y; Kitamura H; Nishiyama H;
BMC Cancer; 2021 Mar; 21(1):266. PubMed ID: 33706705
[TBL] [Abstract][Full Text] [Related]
29. Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy.
Rentsch CA; Birkhäuser FD; Biot C; Gsponer JR; Bisiaux A; Wetterauer C; Lagranderie M; Marchal G; Orgeur M; Bouchier C; Bachmann A; Ingersoll MA; Brosch R; Albert ML; Thalmann GN
Eur Urol; 2014 Oct; 66(4):677-88. PubMed ID: 24674149
[TBL] [Abstract][Full Text] [Related]
30. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin.
Li R; Sundi D; Zhang J; Kim Y; Sylvester RJ; Spiess PE; Poch MA; Sexton WJ; Black PC; McKiernan JM; Steinberg GD; Kamat AM; Gilbert SM
Eur Urol; 2020 Sep; 78(3):387-399. PubMed ID: 32143924
[TBL] [Abstract][Full Text] [Related]
31. Intravesical electromotive drug administration for non-muscle invasive bladder cancer.
Jung JH; Gudeloglu A; Kiziloz H; Kuntz GM; Miller A; Konety BR; Dahm P
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011864. PubMed ID: 28898400
[TBL] [Abstract][Full Text] [Related]
32. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
33. Possible factors affecting response to intravesical bacillus Calmette-Guérin (Tokyo 172 strain) therapy for carcinoma in situ of the bladder: a multivariate analysis.
Takashi M; Katsuno S; Yuba H; Ohshima S; Wakai K; Ohno Y
Int Urol Nephrol; 1998; 30(6):713-22. PubMed ID: 10195866
[TBL] [Abstract][Full Text] [Related]
34. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
[TBL] [Abstract][Full Text] [Related]
35. Upper tract urothelial carcinoma following intravesical bacillus Calmette-Guérin therapy for nonmuscle-invasive bladder cancer: Results from a multi-institutional retrospective study.
Nishiyama N; Hotta H; Takahashi A; Yanase M; Itoh N; Tachiki H; Miyao N; Matsukawa M; Kunishima Y; Taguchi K; Kitamura H; Masumori N
Urol Oncol; 2018 Jun; 36(6):306.e9-306.e15. PubMed ID: 29550096
[TBL] [Abstract][Full Text] [Related]
36. The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin.
Sfakianos JP; Kim PH; Hakimi AA; Herr HW
J Urol; 2014 Feb; 191(2):341-5. PubMed ID: 23973518
[TBL] [Abstract][Full Text] [Related]
37. Does switching the bacillus Calmette-Guérin strain affect clinical outcome in patients with recurrent non-muscle-invasive bladder cancer after initial bacillus Calmette-Guérin therapy?
Niwa N; Kikuchi E; Matsumoto K; Kosaka T; Mizuno R; Oya M
Urol Oncol; 2018 Jun; 36(6):306.e1-306.e8. PubMed ID: 29530465
[TBL] [Abstract][Full Text] [Related]
38. Maintenance intravesical bacillus Calmette-Guérin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group.
Koga H; Ozono S; Tsushima T; Tomita K; Horiguchi Y; Usami M; Hirao Y; Akaza H; Naito S;
Int J Urol; 2010 Sep; 17(9):759-66. PubMed ID: 20604814
[TBL] [Abstract][Full Text] [Related]
39. Comparison of hyperthermic intravesical chemotherapy and Bacillus Calmette-Guerin therapy in high-risk non-muscle invasive bladder cancer: a matched-pair analysis.
Pazir Y; Esmeray A; Caglar U; Erbin A; Ozgor F; Sarilar O; Akbulut F
Int Urol Nephrol; 2024 Mar; 56(3):957-963. PubMed ID: 37880493
[TBL] [Abstract][Full Text] [Related]
40. A prospective comparative study to assess the efficacy and tolerability of 2 different doses of intravesical bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder cancer.
Sood R; Sharma H; Sharma B; Parekh S; Pujari P; Shewale S
Urol Oncol; 2020 May; 38(5):433-439. PubMed ID: 32037199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
